GlobeNewswire by notified

Correction: Annual report 2022: Progress on all major parameters

Share

(English version of annual report-changed from page 70 to English language instead of Danish language)

FirstFarms A/S delivers the best result since the stock exchange listing in 2006 and progress for the 7th year in a row.

FirstFarms has in 2022 realised:
o A turnover of 418 mDKK         (2021: 370 mDKK)
o An EBITDA of 147 mDKK         (2021: 114 mDKK)
o An EBIT of 96 mDKK                 (2021: 70 mDKK)
o A pre-tax result of 84 mDKK         (2021: 46 mDKK)

The equity has increased from 530 mDKK to 683 mDKK. The total capital increase amounts to 153 mDKK. The Group thus ends up with a solvency ratio of 51% at the end of 2022.

The Board of Directors and Management of FirstFarms A/S have today reviewed and adopted the annual report for 20222, and recommends to the general meeting, that dividend of 0.95 DKK per share is paid to the company’s shareholders.

2022 – a good year for FirstFarms
The satisfactory and significantly improved result for 2022 has been achieved despite unpredictable market conditions, drought and high inflation. The result is driven by record-high milk and crop prices, reasonable pig prices, high efficiency, risk diversification and skilled employees.

"The good prices for our products are supported by the initiatives, well-functioning circular operation and high efficiency in all branches of operations. At the same time, all employees and managers once again delivered a dedicated effort," says CEO of FirstFarms, Anders H. Nørgaard.

“Our strategic decision, to diversify risks geographically and across branches of operations, again proves to be of significant importance to our results and the value we create for the Group and our shareholders. For example, the harvest yield in Romania was unsatisfactory due to drought, but nevertheless we took advantage of the high prices for crops in the market, as the harvest yield in the Czech Republic and Slovakia was at a satisfactory level overall," Anders H. Nørgaard continues and emphasises:
"Continued risk diversification is one of the keys to future growth and thus further value creation."

Great activity
2022 was a year of great activity. Among other things:

  • FirstFarms acquired the crop production FirstFarms HunAgro (previously Try-Béta) – a clear strengthening of the circular operation in Hungary.
  • FirstFarms initiated the construction of two new pig productions also in Hungary. The construction is near to be completed and will be put into use in May 2023.
  • FirstFarms inaugurated a new 12,000 tons modern crop plant in Slovakia.

FirstFarms also initiated several solar cell projects – the kick off for a transition to green energy to make the Group as energy-sustainable as possible.

Expectation for 2023

FirstFarms expects a stable 2023 and a satisfactory result with an EBITDA of 90-120 mDKK and an EBIT of 45-75 mDKK against a realised EBITDA of 147 mDKK and an EBIT of 96 mDKK in 2022.

Success in 2023 depends on the ability to continue to deliver high efficiency and productivity throughout the operation, as well as sales prices below the level realised in 2022. The focus will be on creating as much value as possible in the circular operation and value chains around FirstFarms’ products.

It is expected that the Group will be challenged by high purchase prices in the field production and a generally high level of costs compared to 2022. At the same time, the result is negatively affected by the ramp up costs of the expansion of the pig production in Hungary. The production is fully operational by the end of 2023.

The work towards a more sustainable agriculture continues, and our green transition is intensified.

FirstFarms has a goal to become one of Europe’s best operated and most profitable companies in the area of agriculture and food products, and the ambition is continued growth.

FirstFarms’ annual report can be seen in its full length in the attached file.

Best regards,
FirstFarms A/S

For further information:
Please visit our websitewww.firstfarms.comor contact CEO Anders H. Nørgaard on phone +45 75 86 87 87.

About FirstFarms:
FirstFarms is a Danish stock exchange listed company. We operate FirstFarms with responsibility for the surrounding communities, and we deliver highest quality which is primarily sold locally. We act on new opportunities, that create value for our investors and for the surroundings. Every day, we work on creating a more sustainable company.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Baltic Horizon Fund consolidated audited results for 202329.3.2024 10:35:00 CET | Press release

Management Board of Northern Horizon Capital AS has approved the audited financial results of Baltic Horizon Fund (the Fund) for the year 2023. The financial results remained unchanged compared to the preliminary disclosure on 15 February 2024. Executing our strategy In a challenging economic landscape characterized by inflation, interest rate volatility, and recent geopolitical events, the Fund has assessed various strategic options to navigate these complexities and ensure future growth. Over the past year, our focus has been on reshaping our strategy to foster sustainable value, concentrating efforts on avenues that promise reliable and consistent growth for our investors. In light of prevailing market conditions, we firmly believe that the execution of the ‘Modern City Life’ strategy, introduced to investors in summer 2023, is paramount to their best interests. In the coming years, we expect two thirds of the Fund’s NOI to come from the centrally located ‘Modern City Life’ multi-fu

Progress on ABN AMRO share buyback programme 22 – 28 March 202429.3.2024 08:00:00 CET | Press release

Progress on ABN AMRO share buyback programme 22 – 28 March 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 22 March 2024 up to and including 28 March 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €15.47 for a total amount of €46,409,760.00. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly reports, see the ABN AMRO website at https://www.abnamro.com/en/investor-relations/information/share-buyback-programme. To date the total consideration for shares and depositary receipts repurchased amounts to €279,519,000.00 representing 55.9% of the overall share buyback programme. ABN AMRO Press Office pressrelations@nl.abnamro.com +31 20 6288900ABN AMRO Investor Relations investorrelations@nl.abnamro.com +31 20 6282282 This press release is published by ABN AMRO Ba

Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind29.3.2024 07:00:00 CET | Press release

Press release Brussels, 29 March 2024 Regulated information – Inside information Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind On 20 November 2023, Orange Belgium SA (the “Company”) received notification from Nethys SA (“Nethys”) of its wish to contribute its 25% + 1 shareholding in VOO Holding SA (“VOO”) to the capital of the Company, provided that such contribution results in Nethys holding at least 11% of the Company's share capital (after contribution), pursuant to the provisions of the shareholders' agreement entered into by and between the Company, Atlas Services Belgium SA (“ASB”) and Nethys on 2 June 2023. Nethys can be considered a “related” party to the Company within the meaning of the IAS standards, as it has significant influence over VOO within the meaning of IAS and VOO is part of the group to which the Company belongs. Date and value of the planned t

McWhorter Foundation Combats Nelson Peltz’s Outdated Ideologies and Advocates for Sustainable Inclusivity In Corporate Leadership29.3.2024 06:59:56 CET | Press release

PALM BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- C.K. McWhorter, chairman of the McWhorter Foundation, voices concerns over outdated perspectives in corporate leadership, exemplified by recent remarks from Nelson Peltz regarding Disney's film direction. After encountering instances of racism and exclusivity on Town of Palm Beach Island (known as home to Jeffrey Epstein, Nelson Peltz and others), McWhorter reflects on the disconnect between elite boardroom discussions and the realities faced by diverse communities. While briefly meeting Nelson Peltz and shaking hands after both departed separate lunches, McWhorter initially respected his insights. However, recent comments made by Peltz suggesting Disney should avoid inclusive films have raised eyebrows and prompted McWhorter to speak out. "It's concerning when influential figures like Peltz advocate against inclusivity in entertainment," McWhorter comments. "The future is in diversity and representation, especially as millennial a

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates29.3.2024 05:24:27 CET | Press release

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue was approximately RMB1,503 million during 2023. The revenue from pharmaceutical products increased by approximately 58% compared to 2022. The sales revenue of TUOYI® (toripalimab) was approximately RMB919 million, representing an increase of approximately 25% compared to the previous year.Total research and development (“R&D”) expenses were approximately RMB1,937 million in 2023, representing a decrease of approximately 19% compared to 2022. The decrease in R&D expenses was mainly due to the strategic management of R&D investments in certain early-stage pipelines, while optimizing resource all

HiddenA line styled icon from Orion Icon Library.Eye